Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene
about
sameAs
Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL)Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemiaNew microRNAs from mouse and humanArray-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arraysMicroRNAs in mouse models of lymphoid malignanciesMurine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse modelAbnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB miceChromosomal rearrangements and microRNAs: a new cancer link with clinical implicationsInflamma-miRs in Aging and Breast Cancer: Are They Reliable Players?Causes and consequences of microRNA dysregulation in cancerThe New Zealand black mouse as a model for the development and progression of chronic lymphocytic leukemia.Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene.MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers.Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB.The Role of MicroRNAs in Regulatory T Cells and in the Immune Response.MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease.A Single-Array-Based Method for Detecting Copy Number Variants Using Affymetrix High Density SNP Arrays and its Application to Breast CancerDownregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes.ARLTS1 polymorphisms and basal cell carcinoma of the skin.The next thing in prognostic molecular markers: microRNA signatures of cancer.Molecular basis of CLLThe roles of microRNAs in tumorigenesis and angiogenesis.Regulation of innate immune signalling pathways by the tripartite motif (TRIM) family proteins.miR deregulation in CLL.Role of miR-15/16 in CLL.MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?Cellular and viral microRNAs in sepsis: mechanisms of action and clinical applications.Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma.Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemiamiRNA-mediated deregulation in leukemia.Cell-to-cell communication: microRNAs as hormones.TRIM proteins in blood cancers.BCL2 and miR-15/16: from gene discovery to treatment.Key questions about the checkpoint blockade-are microRNAs an answer?
P2860
Q21562355-00FE3A4A-1D81-4F07-97AB-FCC9DEB9FD5EQ24539231-4613AE48-4F0A-4F77-A192-951D6780170FQ24540176-AEC7FCF6-E8A1-44DB-914A-92C8265DFF29Q24614789-124E110E-D815-4D9F-ABC6-54F3D8F38497Q24618980-DD633F1F-A06E-4631-99A0-143874BE1258Q24649526-1E58FEDE-D309-4E49-9A62-3FFF04BC8075Q24675006-97CA435D-E825-40A0-9E68-159967B8218AQ24683729-465506C9-01B7-4D78-BE41-0A59E40017A0Q26772219-5B6FA13A-6B06-4348-A784-410A47158D70Q28258994-DCC8959C-E2C6-4E19-B507-14AA27B6C836Q33691885-687E8195-CE6C-46F9-95DB-D22605C1F634Q33886894-D0233C9C-B967-4CE1-BA09-E95EE1128AB5Q33962495-5988A3D9-CDCB-4EFC-BED0-3225D71748BEQ34671934-8011FD2C-C0E5-4FF4-B2B4-BCF12B4B152BQ34772265-B7E608BF-86C4-430C-99F8-B96FF90527B2Q35157020-07807799-A8CB-4D0E-82D9-05ABB28FCFC0Q35900958-BAC2B6BC-24B0-4FDB-9D53-51E14EEEF54FQ36287377-9A5A58AC-F333-4885-A8E3-316679ADEC71Q36434936-E7DC1848-6AE6-4420-B487-5F8ECC8C0D24Q37330232-068E4EBD-B784-4D19-827E-4AF5D70325B8Q37765383-2F1D2368-FEA9-47DE-BB87-ED8864B8A155Q37791680-9A39CCBE-7B9D-44D8-9CEB-CEA01D1D85A7Q37901391-86A7E987-7E6D-4D65-8871-47DE1428BE85Q37914113-C99273AC-47A3-4622-ABF4-EC4FABE2D896Q38135352-D0AA0351-4632-4FE7-BD4D-C6463432EFE2Q38223793-C9624A91-CC45-4C69-AB92-1FA585D24A2DQ38797069-BB1B414D-7CBE-4BAB-AA16-8C7ED1B0BCF6Q38980437-41483400-CB8F-4AF5-BC44-5B257309492EQ40914883-04CDAE86-42B3-4BCC-A69E-EB03A960291EQ42394984-22FE75C7-1965-483D-B4A2-2CD8D9693656Q42996940-FEE805D8-99F8-47D6-AC88-1BEE3341B01AQ47113309-E07A2CB6-0BE8-42BB-93D9-7CEFE0FB0622Q47433060-84E57180-ADEB-4847-88BA-BB8C97AB85B8Q49560834-9AA1FF16-9FF7-4CC4-A4CB-6E8E0F47DF40Q55339993-F85B70D7-06B2-446F-A27F-B5FA44AF0997
P2860
Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene
description
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2001
@ast
im September 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 15 September 2001)
@en
vedecký článok (publikovaný 2001/09/15)
@sk
vědecký článek publikovaný v roce 2001
@cs
wetenschappelijk artikel (gepubliceerd op 2001/09/15)
@nl
наукова стаття, опублікована у вересні 2001
@uk
مقالة علمية (نشرت في 15-9-2001)
@ar
name
Characterization of the 13q14 ...... plice variant of the LEU2 gene
@ast
Characterization of the 13q14 ...... plice variant of the LEU2 gene
@en
Characterization of the 13q14 ...... plice variant of the LEU2 gene
@nl
type
label
Characterization of the 13q14 ...... plice variant of the LEU2 gene
@ast
Characterization of the 13q14 ...... plice variant of the LEU2 gene
@en
Characterization of the 13q14 ...... plice variant of the LEU2 gene
@nl
prefLabel
Characterization of the 13q14 ...... plice variant of the LEU2 gene
@ast
Characterization of the 13q14 ...... plice variant of the LEU2 gene
@en
Characterization of the 13q14 ...... plice variant of the LEU2 gene
@nl
P2093
P1433
P1476
Characterization of the 13q14 ...... plice variant of the LEU2 gene
@en
P2093
F Bullrich
L Rassenti
M J Keating
P304
P407
P577
2001-09-15T00:00:00Z